Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19059018 | Zonal and Targeted Methods and Uses for Treating a Post-Traumatic Stress Disorder | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19042887 | GIP/GLP1 AGONIST COMPOSITIONS | January 2025 | May 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19012840 | POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGS | January 2025 | June 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 19005540 | PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLE | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18879948 | NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAME | December 2024 | June 2025 | Allow | 6 | 0 | 0 | Yes | No |
| 18879995 | NOVEL 5-DEHYDRO-2-DEOXYGLUCONOKINASE VARIANT AND METHOD FOR PRODUCING 5�-INOSINIC ACID USING SAME | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 18984162 | CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATION | December 2024 | May 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18980129 | Compositions and Methods for Treating Endocrine Diseases and Disorders | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18972246 | TRADITIONAL CHINESE HERBAL COMPOSITION FOR TREATMENT OF BACTERIAL VAGINOSIS AND PREPARATION METHOD THEREOF | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18970552 | S. PYOGENES CAS9 MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME | December 2024 | May 2025 | Allow | 5 | 1 | 0 | No | No |
| 18963644 | BACILLUS PROTEOLYTICUS CWJ-2-GJ AND APPLICATION THEREOF | November 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18870088 | METHOD FOR PRODUCING GUANIDINO ACETIC ACID (GAA) | November 2024 | February 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18955504 | DESMOPRESSIN ORAL COMPOSITIONS | November 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18949272 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | November 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18948016 | PEONY STAMEN-DODDER COMPOSITE, AND ITS PREPARATION METHOD AND APPLICATION | November 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18942174 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18940031 | Hyaluronidase Enzyme Formulations for High Volume Administration | November 2024 | July 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18940001 | Hyaluronidase Enzyme Formulations for High Volume Administration | November 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18935987 | FOOD COMPOSITION CONTAINING NOVEL ALDEHYDE DEHYDROGENASE FOR IMPROVING MEMORY AND COGNITIVE FUNCTION | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18934450 | ESSENTIAL OIL OF STEMS AND LEAVES OF CHUZHOU CHRYSANTHEMUM AND APPLICATION THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 1 | No | No |
| 18934153 | FILAMENTOUS FUNGUS AND USE THEREOF IN GAS METABOLISM | October 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18933327 | CARBONYL REDUCTASE MUTANT AND ITS APPLICATION | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18926515 | GAME ATTRACTANT AND VARMINT REPELLENT COMPOSITIONS AND METHODS | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18926774 | PHYLLOBACTERIUM MYRSINACEARUM STRAIN N1N2-2 FOR EFFICIENT DEGRADATION OF DIPHENYLARSINIC ACID AND USE THEREOF | October 2024 | May 2025 | Allow | 6 | 2 | 1 | No | No |
| 18859487 | ALDITOL OXIDASE AND APPLICATION THEREOF | October 2024 | February 2025 | Allow | 4 | 0 | 0 | No | No |
| 18919946 | FUSION POLYPEPTIDES FOR PRODUCTION OF 7-DEHYDROCHOLESTEROL AND METHODS OF USE THEREOF | October 2024 | February 2025 | Allow | 4 | 0 | 1 | No | No |
| 18919965 | LACTOBACILLUS ACIDOPHILUS GOLDGUT-LA100 HAVING FUNCTIONS OF LIPID LOWERING, BLOOD GLUCOSE LOWERING AND WEIGHT LOSS AND APPLICATION THEREOF | October 2024 | June 2025 | Allow | 8 | 2 | 0 | No | No |
| 18917707 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18915656 | EVOLVED INTEGRASES AND METHODS OF USING THE SAME FOR GENOME EDITING | October 2024 | June 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18911447 | MEDICINAL MUSHROOM-BASED TOPICAL COMPOSITION | October 2024 | January 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18912061 | INSECT NEUROPEPTIDES 6 | October 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18907606 | ANTIBACTERIAL MODIFIED CHITOSAN-BASED HEMOSTATIC MATERIAL AND METHOD OF MANUFACTURING THE SAME | October 2024 | January 2025 | Allow | 3 | 0 | 1 | No | No |
| 18905498 | KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPIN | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18903864 | THERAPEUTIC POLYPEPTIDE | October 2024 | April 2025 | Allow | 6 | 0 | 1 | No | No |
| 18894673 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | September 2024 | June 2025 | Abandon | 8 | 0 | 1 | No | No |
| 18894385 | COMPOSITION FOR WEIGHT REDUCTION AND BODY FAT REDUCTION, PREPARATION METHOD AND APPLICATION THEREOF | September 2024 | April 2025 | Allow | 6 | 1 | 1 | No | No |
| 18894709 | Compositions and Methods for Making Epigenetic Modifications | September 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18893357 | INCRETIN ANALOGS AND USES THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18886923 | ELECTRO-RESPONSIVE SILK FIBROIN MATERIAL, ELECTRO-RESPONSIVE SILK FIBROIN MICRONEEDLE, INSULIN MICRONEEDLE PATCH HAVING ELECTRO-RESPONSIVE SILK FIBROIN AND PREPARATION METHOD THEREFOR, AND TRANSDERMAL DRUG DELIVERY DEVICE | September 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18886925 | HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEIN | September 2024 | January 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18885661 | POLYMERASE MUTANT AND APPLICATIONS THEREOF | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18847017 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | September 2024 | February 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18846061 | ENZYMATIC METHOD FOR THE PRODUCTION OF L-GLUFOSINATE P-ESTERS | September 2024 | June 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18882341 | CELL WALL HYDROLASES TARGETING C. ACNES | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18882318 | RECOMBINANT CELL WALL HYDROLASES | September 2024 | December 2024 | Allow | 3 | 0 | 1 | No | No |
| 18829566 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | September 2024 | November 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18844892 | METHOD FOR IMPROVING HEALTH CONDITION OF MAMMAL OR FARM ANIMAL | September 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18825195 | GENETIC ENGINEERING BACTERIUM FOR DE NOVO SYNTHESIS OF CIS,CIS-MUCONIC ACID BY TAKING GLUCOSE AS SUBSTRATE AND APPLICATIONS THEREOF | September 2024 | April 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18844070 | METHOD FOR CHARACTERIZING INTERACTION FORCE BETWEEN LIGNIN AND CELLULASE | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18824970 | POLYPEPTIDE WITH ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITY, AND PREPARATION METHOD AND USE THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18824681 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | September 2024 | November 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18820753 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18821389 | YEAST STAGE TANK INCORPORATED FERMENTATION SYSTEM AND METHOD | August 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18821027 | AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALT | August 2024 | May 2025 | Allow | 8 | 2 | 0 | No | No |
| 18820792 | SEMAGLUTIDE IN MEDICAL THERAPY | August 2024 | February 2025 | Allow | 5 | 2 | 0 | No | No |
| 18818974 | METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONS | August 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18818636 | CHITOSAN COMPOSITION AND METHOD OF MANUFACTURING THE SAME | August 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18814865 | DEAMINASES AND VARIANTS THEREOF FOR USE IN BASE EDITING | August 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18815386 | AUTOBIOTIC COMPOSITIONS AND METHOD FOR PROMOTING HEALTHY GUT MICROBIOME | August 2024 | June 2025 | Allow | 9 | 2 | 0 | No | No |
| 18806538 | METHODS OF INHIBITING CANCER GROWTH AND INHIBITING VIRAL INFECTIONS | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18806394 | PROCESSES AND INTERMEDIATES FOR PREPARING TIRZEPATIDE | August 2024 | February 2025 | Allow | 6 | 0 | 1 | No | No |
| 18796479 | Curcuminoid composition of Curcumin-keto, method of preparation and use thereof | August 2024 | November 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18794793 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | August 2024 | January 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18785008 | GRANULE FOR DETECTING OCCULT BLOOD IN PET URINE AND METHOD FOR PREPARING THE SAME | July 2024 | December 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18833176 | METHOD OF DETERMINING GLUCOSE CONCENTRATION | July 2024 | April 2025 | Allow | 9 | 0 | 1 | No | No |
| 18781694 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | July 2024 | April 2025 | Allow | 9 | 1 | 1 | No | No |
| 18778554 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18773936 | OKRA-DERIVED ANTIVIRAL COMPOSITION AND USES THEREOF | July 2024 | May 2025 | Allow | 10 | 0 | 1 | No | No |
| 18774846 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | July 2024 | January 2025 | Allow | 7 | 1 | 1 | No | No |
| 18773066 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | July 2024 | December 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18770533 | MICROORGANISMS AND METHODS FOR THE CONTINUOUS PRODUCTION OF FATTY ACIDS, FATTY ALCOHOLS, AND CULTURED PROTEIN FROM C1 SUBSTRATES | July 2024 | June 2025 | Abandon | 11 | 1 | 1 | No | No |
| 18767461 | SYSTEM AND METHOD FOR CO2 HYDROGENATION USING MULTI-ENZYME IMMOBILIZATION ON MODIFIED METAL-ORGANIC FRAMEWORK (MOF) | July 2024 | February 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18767086 | SUBTERRANEAN WATER BARRIER | July 2024 | February 2025 | Allow | 7 | 1 | 1 | No | No |
| 18764014 | FORMULATIONS AND METHODS FOR SKIN CARE | July 2024 | December 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18762259 | COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSION | July 2024 | April 2025 | Allow | 10 | 1 | 1 | No | No |
| 18757539 | PREPARATION OF A PHOSPHOLIPID COMPOSITION/NANO LIQUID PRODUCT USEFUL IN TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING | June 2024 | October 2024 | Allow | 4 | 1 | 0 | No | No |
| 18757390 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | June 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18755691 | Fusion protein and its preparation method for intermediate polypeptide of Semaglutide | June 2024 | November 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18724136 | IL-4 DERIVED PEPTIDE FRAGMENTS FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHY | June 2024 | June 2025 | Allow | 12 | 2 | 0 | No | No |
| 18723639 | NOVEL PROMOTER VARIANT FOR CONSTITUTIVE EXPRESSION AND USES THEREOF | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18751723 | NPY2 RECEPTOR AGONISTS | June 2024 | May 2025 | Allow | 11 | 0 | 1 | No | No |
| 18749788 | USE OF MUTANT OF IMMUNOGLOBULIN DEGRADING ENZYME IDEE | June 2024 | March 2025 | Allow | 9 | 1 | 1 | No | No |
| 18750994 | COMPOSITIONS FOR INHIBITING ANAEROBIC MICROORGANISMS | June 2024 | November 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18750691 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | June 2024 | March 2025 | Allow | 9 | 2 | 1 | No | No |
| 18721879 | ZAVARZINIA COMPRANSORIS CAPABLE OF DEGRADING ORGANOPHOSPHORUS FLAME RETARDANT AND USE THEREOF | June 2024 | June 2025 | Allow | 12 | 0 | 0 | Yes | No |
| 18747818 | Peptides for Characterization of Botulinum Neurotoxins | June 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18746153 | MUNG BEAN HULL EXTRACT WITH ANTIVIRAL EFFECT AND EXTRACTION METHOD THEREOF | June 2024 | April 2025 | Allow | 10 | 0 | 1 | No | No |
| 18745674 | COMPOSITIONS AND METHOD FOR TREATING AND PREVENTING COMPLICATIONS OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 1 | No | No |
| 18739955 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18717423 | LACTIPLANTIBACILLUS PLANTARUM STRAIN FOR ALLEVIATING HYPERURICEMIA AND COMBINATION AND USE THEREOF | June 2024 | May 2025 | Allow | 11 | 1 | 0 | No | No |
| 18736592 | TRADITIONAL CHINESE MEDICINE COMPOUND FOR PREVENTING AND TREATING AFRICAN SWINE FEVER, AND ITS EFFICIENCY ENHANCEMENT PROCESS AND APPLICATION | June 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18736608 | SEMAGLUTIDE IN MEDICAL THERAPY | June 2024 | January 2025 | Abandon | 7 | 0 | 0 | No | No |
| 18736009 | PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS | June 2024 | January 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18735209 | METHOD FOR SELECTING AEROBIC DENITRIFYING FUNGUS AND METHOD FOR REMEDIATING WATER BODY WITH LOW CARBON-TO-NITROGEN RATIO USING AEROBIC DENITRIFYING FUNGUS | June 2024 | February 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18734282 | HYBRID GEL COMPRISING PARTICULATE DECELLULARIZED TISSUE | June 2024 | July 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18733907 | URINARY SYSTEM CATHETER USING ETHANOL EXTRACT OF PROPOLIS AS COATING AND PREPARATION METHOD THEREOF | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18734602 | PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18734239 | METHOD FOR EXPANDING PROPAGATION OF METARHIZIUM RILEYI MR006 AND USE THEREOF | June 2024 | April 2025 | Allow | 10 | 2 | 0 | No | No |
| 18733576 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | June 2024 | September 2024 | Allow | 3 | 1 | 0 | No | No |
| 18731571 | IMMOBILIZED ENZYMES FOR BIOELECTROCATALYSIS | June 2024 | July 2025 | Allow | 13 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1650.
With a 33.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1650 is part of Technology Center 1600. This group has examined 95,813 patent applications in our dataset, with an overall allowance rate of 58.9%. Applications typically reach final disposition in approximately 32 months.
Applications in Group 1650 receive an average of 1.82 office actions before reaching final disposition. The median prosecution time is 32 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.